The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

by Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W. M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J. G. van de Werken, Niven Mehra, Martijn P. Lolkema
Published 2019

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

by Mariaelena Pierobon, Johann De Bono, Ruth Riisnaes, Giuseppe Giaccone, Matthew Blackburn, Lance Liotta, Vienna Ludovini, Neil J Shah, Giuseppina Improta, Antonella Ravaggi, Niven Mehra, Angelo Sidoni, Elisa Baldelli, K Alex Hodge, Guido Bellezza, Guido Gambara, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Franco Odicino, Maria Isabella Sereni, Angela Zupa, Perry Demsko, Lucio Crino', Emanuel F Petricoin
Published 2021

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

by Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Published 2021